目的 探討益腎化濕顆粒聯(lián)合布美他尼片治療慢性腎小球腎炎的治療效果。方法 選取2020年5月-2023年4月溧陽市人民醫(yī)院收治的120例慢性腎小球腎炎患者,按照計算機隨機排列法將所有患者分為對照組(60例)和治療組(60例)。對照組口服布美他尼片,2片/次,3次/d。治療組在對照組基礎(chǔ)上溫水沖服益腎化濕顆粒,1袋/次,3次/d。兩組患者持續(xù)治療3個月。觀察兩組患者的臨床療效,比較兩組的癥狀改善情況、腎功能和血清指標。結(jié)果 治療組的總有效率(91.67%)明顯高于對照組(78.33%),組間差異顯著(P<0.05)。治療后,治療組患者水腫、血尿、蛋白尿消失時間均比對照組短(P<0.05)。治療后,兩組的腎小球濾過率(GFR)比治療前大,肌酐(Scr)、胱抑素C(Cys-C)、尿蛋白排泄率(UAER)比治療前小(P<0.05);治療組的GFR比對照組大,Scr、Cys-C、UAER比對照組小(P<0.05)。治療后,兩組的血清中性粒細胞明膠酶相關(guān)性載脂蛋白(NGAL)、單核細胞趨化蛋白-1(MCP-1)、白細胞誘素-1(Lkn-1)水平均比治療前小(P<0.05);治療組的血清NGAL、MCP-1、Lkn-1水平比對照組小(P<0.05)。結(jié)論 益腎化濕顆粒聯(lián)合布美他尼片可提高慢性腎小球腎炎的臨床療效,顯著減輕臨床癥狀,改善腎功能,降低腎組織炎癥損傷。

Objective To explore the therapeutic effect of Yishen Huashi Granules and Bumetanide Tablets in treatment of chronic glomerulonephritis. Method Patients (120 cases) with chronic glomerulonephritis in Liyang People's Hospital from May 2020 to April 2023 were divided into control and treatment groups according to the computer random arrangement method, and each group had 60 cases. Patients in the control group were po administered with Bumetanide Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Yishen Huashi Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the symptom improvement, renal function, and serum markers in two groups were compared. Results The total effective rate of the treatment group (91.67%) was significantly higher than 78.33% of the control group, with significant difference between groups (P < 0.05). After treatment, the disappearance time of edema, hematuria, and proteinuria in the treatment group was shorter than that in the control group (P < 0.05). After treatment, the levels of GFR in two groups were higher than before treatment, but the levels of Scr, Cys-C, and UAER were lower than before treatment (P < 0.05). The levels of GFR in the treatment group were higher than that in the control group, but the levels of Scr, Cys-C, and UAER in the treatment group were higher than those in the control group (P < 0.05). After treatment, the serum levels of NGAL, MCP-1, and Lkn-1 in two groups were lower than before treatment (P < 0.05), and the serum levels of NGAL, MCP-1, and Lkn-1 in the treatment group were lower than those in the control group (P < 0.05). Conclusion Yishen Huashi Granules and Bumetanide Tablets in treatment of chronic glomerulonephritis can improve the clinical efficacy of chronic glomerulonephritis, significantly reduce clinical symptoms, improve renal function, and reduce the damage of renal tissue inflammation.

R983